COMPANY Data
Movers and SHAKERS

Ticker | CTXR (Nasdaq) |
Current Price | $1.29 ↑ 0.11 |
Market Cap | 187.78M |
Volume | 618.13k |
52wk Range | $0.83 - $2.35 |
ADVANCED MARKET DATA |

Advanced Market Data
Citius Pharmaceuticals Inc. (CTXR)Overview
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.
- Citius Pharmaceuticals press release ( NASDAQ: CTXR ): Q3 GAAP EPS of -$0.06.
- The company has reported $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023
For further details see:
Citius Pharmaceuticals GAAP EPS of -$0.06Citius Pharmaceuticals Inc. Corporate Filings
Citius Pharmaceuticals Inc. Corporate Events
Citius Pharmaceuticals Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available